She was diagnosed with rheumatoid arthritis at the age of 35."
她在35岁时被诊断为类风湿关节炎。
RA patients often experience joint inflammation and stiffness.
类风湿关节炎患者经常经历关节炎症和僵硬。
Her
RA has been in remission for two years now.
她的类风湿关节炎已经缓解了两年。
The doctor prescribed a DMARD for her
RA treatment.
医生给她开了一个DMARD来治疗类风湿关节炎。
Regular exercise can help manage the symptoms of
RA.
定期锻炼可以帮助管理类风湿关节炎的症状。
RA primarily affects the joints, but can also impact other organs.
类风湿关节炎主要影响关节，但也可能影响其他器官。
She noticed an improvement in her
RA after switching to a plant-based diet.
她改变为植物性饮食后，发现自己的类风湿关节炎有所改善。
The patient's
RA is well-controlled with a combination of medication and therapy.
通过药物和理疗的结合，患者的类风湿关节炎得到了很好的控制。
RA can be a chronic condition that requires ongoing management.
类风湿关节炎可能是一种需要持续管理的慢性病。
Research continues into new treatments for
RA to improve patients' quality of life.
对类风湿关节炎的新疗法研究仍在进行中，以提高患者的生活质量。
United States-based pharmaceutical company Pfizer Inc supported the launch of China's first rheumatoid arthritis development report, in an effort to promote the country's RA diagnosis and treatment level.
美国制药公司辉瑞(Pfizer Inc.)支持发布了中国首份风湿性关节炎发展报告，以提升中国在该领域的诊断和治疗水平。
The report is based on the real world data of over 50,000 RA patients from more than 300 hospitals in China.
这份报告基于中国300多家医院超过50,000名类风湿性关节炎(RA)患者的现实世界数据。
It comprehensively displays the latest epidemiological data, clinical features, disease diagnosis and treatment, discipline resources and construction status, and opportunities and challenges of China's RA.
它全面展示了中国RA（风湿性关节炎）最新的流行病学数据、临床特征、疾病诊断和治疗、学科资源和建设状况，以及机遇和挑战。
It is hoped that the report can raise China's RA standardized diagnosis and treatment level and long-term management level, and improve the quality of life of patients with rheumatic immune diseases.
期望该报告能提升中国风湿免疫疾病的标准诊断和治疗水平以及长期管理水平，从而提高患者的生活质量。
According to the report, there are currently around 5 million RA patients in China.
根据报告，目前中国大约有500万RA（类风湿关节炎）患者。
Zeng Xiaofeng, director of the rheumatology and immunology department of Peking Union Medical College Hospital, said: "RA is a common disease in China.
北京协和医院风湿免疫科主任曾小峰表示：“RA在中国是一种常见病。
Because of late discipline construction, lack of medical professionals and disease awareness, there is a certain gap between China and the international advanced level in RA standardized diagnosis and treatment and follow-up management.
由于风湿病学科建设起步较晚、医疗专业人员匮乏以及疾病认知度不足，我国在RA标准化诊治和随访管理方面与国际先进水平存在一定差距。
""The report covers RA patient data from both national 3A-grade hospitals to grass root-level medical institutions in China.
该报告涵盖了中国从国家级三甲医院到基层医疗机构的RA（类风湿关节炎）患者的数据。
It is beneficial to raising the country's RA diagnosis and treatment level and bringing patients benefits," he said.
“这有利于提高我国RA的诊断和治疗水平，使患者受益。”他说。
Tian Xinping, chief physician of the rheumatology and immunology department of Peking Union Medical College Hospital, said: "As noted by the report, RA is becoming a heavy burden for patients and their families, and even the whole society.
北京协和医院风湿免疫科主任医师田新平表示：“正如报告所指出的，类风湿关节炎正成为患者及其家庭，甚至整个社会的沉重负担。”
Although so far, RA cannot be completely cured, early treatment can help patients achieve disease remission, avoid or delay the occurrence of irreversible damage, and improve long-term prognosis.
尽管目前RA还无法完全治愈，但早期治疗可以帮助患者达到疾病缓解，避免或延迟不可逆的损伤发生，并改善长期预后。
In the recent years, through constant exploration, we have established an increasingly complete pipeline of innovative drugs in the inflammation and immunity field, covering diseases such as RA, ankylosing spondylitis, atopic dermatitis, and alopecia areata.
近年来，通过持续探索，我们在炎症与免疫领域建立起日趋完善的创新药物管线，覆盖了包括类风湿关节炎、强直性脊柱炎、特应性皮炎和斑秃等疾病。
""With the launch of the report, it is expected that efforts can be joined to make China's RA standardized diagnosis and treatment in line with the international advanced level," he said.
他指出，“随着报告的发布，我们期待可以共同努力，使中国的类风湿关节炎诊断和治疗达到国际先进水平。”
Belgium-based global biopharmaceutical company UCB announced the commercial launch of an innovative biological therapy to treat moderate-to-severe active rheumatoid arthritis (RA) for adult patients in China, marking the expansion of company's business footprint to immune system diseases in the country.
The injection that patients are suggested to take every two weeks is the first biological agent approved in China to be used for female RA patients both during pregnancy and lactation if clinically needed.
Doctors said RA is an autoimmune disease that causes chronic joint inflammation and affects 5 million people in China.
RA also comes with high disease relapse rate after giving birth, she said.